|
|
|
|
|
|
|
|
|
|
|
11.11.25 - 23:00
|
Prokarium ernennt Ibs Mahmood zum Chief Executive Officer (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--Prokarium ist ein auf die klinische Phase spezialisiertes biopharmazeutisches Unternehmen für den Bereich mikrobielle Immuntherapie. Das Unternehmen hat heute die Ernennung von Ibs Mahmood zum Chief Executive Officer (CEO) bekannt gegeben. Ibs folgt Kristen Albright nach, der dem Board of Directors beitritt, um weiterhin die strategische Richtung von Prokarium mitzubestimmen.
Ibs kann auf 25 Jahre als Unternehmer in der Biotechnologie zurückblicken. Er hat mehrere Life-Science-Unternehmen gegründet und durch die klinische Entwicklung, die Finanzierungsphase und die strategische Ausrichtung geführt. Er hat mehr als $300 Millionen für eigene Unternehmungen und mehr als $2 Milliarden für Kunden aufgebracht. Er hat die Unternehmen AMO Pharma, DrugDev und Induction Healthcare mitgegründet und geführt. Darüber hinaus hatte er Führungspositionen bei IQVIA, Abingworth, Shire Pharma und Investec inne. Ibs hat an der University of Oxford Medizin gelehrt.
„Ibs' Ernennung markier...
|
|
|
|
|
11.11.25 - 13:09
|
Prokarium Appoints Ibs Mahmood as Chief Executive Officer (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kristen Albright, who will join the Board of Directors to continue shaping Prokarium's strategic direction.
Ibs brings 25 years as a biotechnology entrepreneur having founded and led multiple life science companies through clinical development, financing and strategic transactions, raising more than $300 million for his own ventures and over $2 billion for clients. He previously co-founded and led AMO Pharma, DrugDev and Induction Healthcare, and enjoyed senior roles at IQVIA, Abingworth, Shire Pharma and Investec. Ibs read medicine at the University of Oxford.
“Ibs' appointment marks an important step in Prokarium's evolution. His unique blend of medical insight, entrepreneurial drive and industry experience will help us accelerate our mission to change the treatment paradigm in bl...
|
|
|
05.11.25 - 22:18
|
Dr. William G. Kaelin Jr. joins IQVIA Board of Directors (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today.
Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women's Hospital in Boston and the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. He is also an Investigator at the Howard Hughes Medical Institute. In 2019, Dr. Kaelin was awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work on oxygen sensing and the role of the von Hippel-Lindau (VHL tumor) suppressor protein. He currently serves on the board of directors of Eli Lilly and Company, where he chairs the Science and Technology Committee.
“I am very pleased to welcome Bill to our board of directors,” said Ari Bousbib, chairman and CEO, IQVIA. “Bill is a world-renowned scientist and physician with deep e...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.10.25 - 12:06
|
IQVIA Reports Third-Quarter 2025 Results (Business Wire)
|
|
|
Revenue of $4,100 million, up 5.2 percent year-over-year
GAAP Net Income of $331 million, Adjusted EBITDA of $949 million
GAAP Diluted Earnings per Share of $1.93, Adjusted Diluted Earnings per Share of $3.00
R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.15x
R&D Solutions contracted backlog of $32.4 billion, up 4.1 percent year-over-year
Operating Cash Flow of $908 million; Free Cash Flow of $772 million, up 35 percent year-over-year, representing 150 percent of Adjusted Net Income
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30, 2025.
Third-Quarter 2025 Operating Results
Revenue for the third quarter of $4,100 million increased 5.2 percent on a reported basis and 3.9 percent at constant currency, comp...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
